用于脑肿瘤的树突状细胞疫苗。
Dendritic cell vaccines for brain tumors.
作者信息
Kim Won, Liau Linda M
机构信息
UCLA Department of Neurosurgery, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, CHS 74-145, Los Angeles, CA 90095-6901, USA.
出版信息
Neurosurg Clin N Am. 2010 Jan;21(1):139-57. doi: 10.1016/j.nec.2009.09.005.
Abstract
Over the past decade, dendritic cell-based immunotherapy for central nervous system tumors has progressed from preclinical rodent models and safety assessments to phase I/II clinical trials in over 200 patients, which have produced measurable immunologic responses and some prolonged survival rates. Many questions regarding the methods and molecular mechanisms behind this new treatment option, however, remain unanswered. Results from currently ongoing and future studies will help to elucidate which dendritic cell preparations, treatment protocols, and adjuvant therapeutic regimens will optimize the efficacy of dendritic cell vaccination. As clinical studies continue to report results on dendritic cell-mediated immunotherapy, it will be critical to continue refining treatment methods and developing new ways to augment this promising form of glioma treatment.
摘要
在过去十年中，基于树突状细胞的中枢神经系统肿瘤免疫疗法已从临床前啮齿动物模型和安全性评估发展到针对200多名患者的I/II期临床试验，这些试验产生了可测量的免疫反应和一些延长的生存率。然而，关于这种新治疗选择背后的方法和分子机制的许多问题仍未得到解答。目前正在进行的和未来的研究结果将有助于阐明哪种树突状细胞制剂、治疗方案和辅助治疗方案将优化树突状细胞疫苗接种的疗效。随着临床研究不断报告树突状细胞介导的免疫疗法的结果，持续改进治疗方法并开发新方法以增强这种有前景的胶质瘤治疗形式将至关重要。
相似文献
1
Dendritic cell vaccines for brain tumors.用于脑肿瘤的树突状细胞疫苗。
Neurosurg Clin N Am. 2010 Jan;21(1):139-57. doi: 10.1016/j.nec.2009.09.005.
2
Dendritic cell vaccines.树突状细胞疫苗。
Adv Exp Med Biol. 2012;746:187-200. doi: 10.1007/978-1-4614-3146-6_15.
3
Dendritic-cell- and peptide-based vaccination strategies for glioma.基于树突状细胞和肽的胶质瘤疫苗接种策略
Neurosurg Rev. 2009 Jul;32(3):265-73; discussion 273. doi: 10.1007/s10143-009-0189-1. Epub 2009 Feb 13.
4
Novel Immunotherapeutics for Treatment of Glioblastoma: The Last Decade of Research.用于治疗胶质母细胞瘤的新型免疫疗法：过去十年的研究
Cancer Invest. 2019;37(1):1-7. doi: 10.1080/07357907.2018.1479414. Epub 2019 Jan 11.
5
Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review.基于树突状细胞的恶性胶质瘤治疗疫苗：一项系统综述
Cancer Invest. 2014 Nov;32(9):451-7. doi: 10.3109/07357907.2014.958234. Epub 2014 Sep 26.
6
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.新冠疫苗的快速研发和早期成功为加速癌症治疗机制带来了希望。
Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1.
7
Dendritic cell immunotherapy for malignant gliomas.用于恶性胶质瘤的树突状细胞免疫疗法。
Rev Recent Clin Trials. 2008 Jan;3(1):10-21. doi: 10.2174/157488708783330530.
8
Immunotherapy for glioma: getting closer to the clinical arena?免疫疗法治疗脑胶质瘤：离临床应用更近了？
Curr Opin Neurol. 2011 Dec;24(6):641-7. doi: 10.1097/WCO.0b013e32834cbb17.
9
The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.基于细胞和病毒的免疫疗法在恶性胶质瘤中的潜力——树突状细胞疫苗、过继性细胞转移和溶瘤病毒
Curr Neurol Neurosci Rep. 2017 Jun;17(6):50. doi: 10.1007/s11910-017-0754-x.
10
Clinical applications of dendritic cell vaccination in the treatment of cancer.树突状细胞疫苗接种在癌症治疗中的临床应用
Cancer Immunol Immunother. 2004 Apr;53(4):275-306. doi: 10.1007/s00262-003-0432-5. Epub 2003 Nov 26.
引用本文的文献
1
Delivery strategies for cell-based therapies in the brain: overcoming multiple barriers.脑内细胞治疗的传递策略：克服多重障碍。
Drug Deliv Transl Res. 2021 Dec;11(6):2448-2467. doi: 10.1007/s13346-021-01079-1. Epub 2021 Oct 30.
2
Immunotherapy for Medulloblastoma: Current Perspectives.髓母细胞瘤的免疫治疗：当前观点
Immunotargets Ther. 2020 Apr 20;9:57-77. doi: 10.2147/ITT.S198162. eCollection 2020.
3
The role of the immune system in brain metastasis.免疫系统在脑转移中的作用。
Curr Neurobiol. 2019 Jul;10(2):33-48.
4
Therapeutic Interventions in Adult Low-Grade Gliomas.成人低级别胶质瘤的治疗干预措施
J Clin Neurol. 2019 Jan;15(1):1-8. doi: 10.3988/jcn.2019.15.1.1. Epub 2018 Sep 6.
5
Dendritic Cells as an Alternate Approach for Treatment of Neurodegenerative Disorders.树突状细胞作为治疗神经退行性疾病的一种替代方法。
Cell Mol Neurobiol. 2018 Aug;38(6):1207-1214. doi: 10.1007/s10571-018-0598-1. Epub 2018 Jun 13.
6
miR-181d regulates human dendritic cell maturation through NF-κB pathway.微小RNA-181d通过核因子κB途径调节人树突状细胞成熟。
Cell Prolif. 2017 Oct;50(5). doi: 10.1111/cpr.12358. Epub 2017 Jul 21.
7
Engineering challenges for brain tumor immunotherapy.脑肿瘤免疫治疗的工程挑战。
Adv Drug Deliv Rev. 2017 May 15;114:19-32. doi: 10.1016/j.addr.2017.06.006. Epub 2017 Jun 15.
8
Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response.多形性胶质母细胞瘤的树突状细胞疫苗接种：聚焦治疗反应预测因素的综述
Immunotargets Ther. 2014 Mar 13;3:55-66. doi: 10.2147/ITT.S40121. eCollection 2014.
9
Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme.基于树突状细胞的多形性胶质母细胞瘤免疫治疗
Biomed Res Int. 2015;2015:717530. doi: 10.1155/2015/717530. Epub 2015 Jun 17.
10
Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.用于增强免疫疗法治疗多形性胶质母细胞瘤的纳米技术。
J Neurooncol. 2015 Jul;123(3):473-81. doi: 10.1007/s11060-015-1814-1. Epub 2015 Jun 13.
本文引用的文献
1
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).实体瘤新的疗效评价标准：修订的RECIST指南（第1.1版）
Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
2
Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters.恶性黑色素瘤患者基于树突状细胞疫苗接种的临床研究综述：临床反应与疫苗参数之间的相关性评估
Cancer Immunol Immunother. 2009 Jan;58(1):1-14. doi: 10.1007/s00262-008-0568-4. Epub 2008 Aug 22.
3
Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients.疫苗接种在多形性胶质母细胞瘤患者中引发了相关的免疫和临床反应。
Cancer Res. 2008 Jul 15;68(14):5955-64. doi: 10.1158/0008-5472.CAN-07-5973.
4
Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.复发性多形性胶质母细胞瘤患者术后基于树突状细胞的辅助免疫治疗
Clin Cancer Res. 2008 May 15;14(10):3098-104. doi: 10.1158/1078-0432.CCR-07-4875.
5
Cell- and peptide-based immunotherapeutic approaches for glioma.基于细胞和肽的神经胶质瘤免疫治疗方法。
Trends Mol Med. 2008 May;14(5):228-35. doi: 10.1016/j.molmed.2008.03.003. Epub 2008 Apr 9.
6
Immunotherapy of malignant brain tumors.恶性脑肿瘤的免疫治疗
Immunol Rev. 2008 Apr;222:70-100. doi: 10.1111/j.1600-065X.2008.00603.x.
7
Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy.恶性星形细胞瘤I期树突状细胞疫苗试验结果：与辅助化疗的潜在相互作用
J Clin Neurosci. 2008 Feb;15(2):114-21. doi: 10.1016/j.jocn.2007.08.007.
8
Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model.在小鼠胶质瘤模型中，清除调节性T细胞对于用肿瘤裂解物脉冲树突状细胞进行有效疫苗接种至关重要。
Int J Cancer. 2008 Apr 15;122(8):1794-802. doi: 10.1002/ijc.23284.
9
Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells.在用负载肿瘤裂解物的树突状细胞刺激后，Th1定向效应细胞的胶质瘤生长抑制活性需要持续产生白细胞介素-10。
J Neurooncol. 2007 Sep;84(2):131-40. doi: 10.1007/s11060-007-9362-y. Epub 2007 Mar 15.
10
Dendritic cell vaccination in patients with malignant gliomas: current status and future directions.恶性胶质瘤患者的树突状细胞疫苗接种：现状与未来方向
Neurosurgery. 2006 Nov;59(5):988-99; discussioin 999-1000. doi: 10.1227/01.NEU.0000245595.38957.3E.
Zotero 插件